Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05345327 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Study acronym: START
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 20, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study sites: 3 to 8 Eligibility criteria revised · Secondary endpoints: 7 to 8 · Study description expanded, about 2 wordsv3 Show 3 more changesShow less
    • Eligibility criteria revised
    • Secondary endpoints: 7 to 8
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 1, 2022 to Jan 1, 2023 · Study sites: 2 to 3 · Eligibility criteria shortened, about 7 wordsv2 Show 3 more changesShow less
    • Start date changed from estimate of Jun 1, 2022 to Jan 1, 2023
    • Study sites: 2 to 3
    • Eligibility criteria shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The George Institute
19 trials monitored
See 1 trial at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Type 2 Diabetes
2,100 trials monitored
See 102 trials at risk
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
Trial Details
NCT Number NCT05345327
Lead Sponsor The George Institute
Collaborators: The University of New South Wales, Monash University, University of Sydney
Conditions Type 2 Diabetes
Enrollment 994 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov